Minnesota has no stem cell statute. Searches of Minnesota Statutes and Minnesota Rules return no state law on stem cell therapy advertising or disclosure, so what reaches a provider here is general consumer protection law, physician discipline law, and federal tissue regulation. This guide covers what applies in 2026 and what patients should verify before banking their own adipose tissue.
TLDR Minnesota has no stem cell statute and no state rule on regenerative medicine advertising. Providers here answer to the Minnesota Consumer Fraud Act, the Deceptive Trade Practices Act, physician discipline grounds, and federal law at 21 CFR Part 1271. Nothing derived from adipose tissue is FDA approved for any disease, and banking does not guarantee eligibility, access, or clinical benefit from any future therapy or trial.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. No adipose-derived stem cell product currently has FDA approval for any disease. All content is for educational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions.
Patients looking for a Minnesota stem cell law usually expect a chapter number. There is not one. The statutes do not address these services, and neither do the state rules.
That absence is not a loophole, and it is not permission either. The rules that reach a Minnesota provider come from general consumer protection statutes, the grounds for physician discipline, and federal regulation.
Save My Fat is a connector. It links patients and providers with a United States tissue bank, and it does not collect, process, store, or treat tissue. What follows is a plain reading of the law.
Does Minnesota Have a Stem Cell Law?
No. Minnesota has no statute and no administrative rule on stem cell therapy advertising or disclosure. Each search below was validated with a control query first, which is the only way a negative result means anything.
Searching Minnesota Statutes returns exactly two documents, sections 256B.0625 and 256B.06, both Medicaid coverage provisions. The single hit for “regenerative” is section 18C.71, Minnesota Agricultural Fertilizer Research. That is agriculture, not medicine.
Narrowing the query does not change the answer. A regenerative medicine search returns “No Documents Found,” and so does an exosome search. Minnesota Rules return the same for “stem cell” and “regenerative.” Chapters 147, 325D and 325F contain zero occurrences of “stem cell.”
Is Regenerative Medicine Minnesota a Regulation?
No. It is a research grant program, not a regulatory statute. It was created by an appropriation, Laws of Minnesota 2014, chapter 312, art. 1, sec. 4, subd. 2, and it is not codified in Minnesota Statutes. It regulates nothing.
A state funded grant program is not a state approval of a therapy, not a license, and not evidence that any product has been reviewed.
What Minnesota Law Does Apply to Providers?
Three general laws do most of the work. None of them names stem cells, and each can reach a false or misleading claim about them.
The Consumer Fraud Act at Minn. Stat. 325F.69 subd. 1 makes a “misleading statement or deceptive practice, with the intent that others rely thereon in connection with the sale of any merchandise” enjoinable, “whether or not any person has in fact been misled, deceived, or damaged thereby.” Minn. Stat. 325D.44, the Deceptive Trade Practices Act, is a second general statute with no stem cell provision.
Physician conduct sits apart from both. Minn. Stat. 147.091(e) lists as grounds for physician discipline “Advertising which is false or misleading, which violates any rule of the board, or which claims without substantiation the positive cure of any disease, or professional superiority to or greater skill than that possessed by another physician.” The unsubstantiated cure claim is named in the statute itself.
What Federal Rules Apply to Every Minnesota Provider?
The same ones that apply everywhere. 21 CFR Part 1271, “Human Cells, Tissues, and Cellular and Tissue-Based Products,” is federal, and no state statute can approve a product, override FDA jurisdiction, or make an unapproved product legal to market.
A product falls under section 361 only if it meets all four Section 361 criteria at 21 CFR 1271.10(a): minimal manipulation, homologous use only, no combination with another article beyond water, crystalloids, or a sterilizing, preserving, or storage agent, and either no systemic effect and no dependence on the metabolic activity of living cells, or autologous, first-degree or second-degree blood relative, or reproductive use.
Anything that fails those criteria and is not otherwise excepted “will be regulated as a drug, device, and/or biological product” under 21 CFR 1271.20. That means an investigational new drug application to study it and a biologics license application to market it.
One detail matters for anyone reading an advertisement. Homologous use is judged by “the labeling, advertising, or other indications of the manufacturer’s objective intent,” so advertising is written into the regulation itself.
How Minnesota Compares to Georgia, Tennessee, and Ohio
Two of those states enacted stem cell statutes in 2026 and two have none. The comparison matters because it shows what a Minnesota patient will not see: a state mandated notice inside the advertisement.
| State | Stem cell statute | What state law requires |
|---|---|---|
| Minnesota | None | No notice or consent mandate; consumer fraud and discipline law apply |
| Ohio | None | No notice or consent mandate; deceptive trade and board rules apply |
| Georgia | HB 1275 (2026 Ga. Laws Act 453), effective July 1, 2026 | Advertising notice, plus consent covering three listed disclosures |
| Tennessee | HB 2246, 2026 Tenn. Pub. Ch. 1016, effective July 1, 2026 for most purposes | Advertising notice, plus a consent form with no contents specified |
In Georgia and Tennessee the only penalty is board discipline, and neither statute approves or legalizes any product. For a Minnesota reader the point is that no one here must hand over that warning. Our state law map covers the wider picture, and the disclosure law comparison sets the notices side by side.
What Advertising Rules Apply to Minnesota Regenerative Medicine Marketing?
Federal advertising law does, and it is stricter than most marketing copy assumes. The FTC’s health products guidance, published December 20, 2022, replaced the 1998 dietary supplements guide and draws on more than 200 FTC cases settled or adjudicated since 1998.
Health benefit claims need “competent and reliable scientific evidence,” meaning studies “conducted and evaluated in an objective manner by experts” and “generally accepted in the profession to yield accurate and reliable results.” Randomized controlled human trials are the most reliable form of evidence. Vague qualifiers such as “may,” “promising,” or “preliminary” are inadequate.
Testimonials do not fill the gap. Consumer endorsements are “not competent and reliable scientific evidence” under 16 CFR 255.2(a), and a “Results not typical” line does not correct deception. Under material connections, an unexpected connection “must be disclosed clearly and conspicuously.”
What Should Minnesota Patients Verify Before Banking?
Start with regulatory status, not marketing language. FDA registration and listing are self-submitted, and they are not approval, endorsement, clearance, or certification. FDA’s patient information page says “the fact that a firm has registered with FDA and listed its product does not mean the product is legally marketed.”
Next, check what is approved. FDA’s roster of approved cellular therapies, last updated August 18, 2026, lists no adipose-derived product for any disease. FDA’s consumer alert adds that no regenerative medicine products are approved for uses including orthopedic conditions, neurological disorders, cardiovascular or pulmonary disease, autism, blindness, or chronic pain, and that no exosome products are approved.
Then understand the limits of the autologous exception. It removes donor screening and testing for cells and tissues for autologous use at 21 CFR 1271.90(a)(1), and nothing more. It is not an exception to registration, listing, current good tissue practice, labeling, or the 1271.10(a) criteria. Stored autologous tissue must be labeled “FOR AUTOLOGOUS USE ONLY” and “NOT EVALUATED FOR INFECTIOUS SUBSTANCES” unless that screening and testing were done.
Finally, take FDA’s plainest sentence seriously. If you are charged for these products, or offered them outside a clinical trial, FDA says you are “likely being deceived and offered a product illegally.” Preserving a patient’s own tissue is not a treatment.
Frequently Asked Questions
Does Minnesota require a stem cell advertising notice?
No. Minnesota has no statute or rule requiring any notice in advertising for these services. Georgia and Tennessee each require one, in type no smaller than the largest type used in the advertisement. Minnesota’s exposure comes from general law instead.
Does banking adipose tissue give a Minnesota patient access to future treatment?
No. Banking preserves a patient’s own tissue for potential future use. It does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program, and any future use would depend on FDA regulatory status, physician guidance, and what pathways exist then.
Do federal rules change because a laboratory sits outside Minnesota?
No. 21 CFR Part 1271 is federal and applies in all 50 states. The classification questions are identical wherever tissue is handled: minimal manipulation, homologous use, what the material was combined with, and stated intent.
Key Takeaways
Minnesota has no stem cell statute and no state rule on regenerative medicine advertising or disclosure. What applies is general law: the Consumer Fraud Act at Minn. Stat. 325F.69 subd. 1, the Deceptive Trade Practices Act at 325D.44, and physician discipline grounds at 147.091(e). Regenerative Medicine Minnesota funds research and regulates nothing. Federal rules at 21 CFR Part 1271 apply here as they do in Georgia, Tennessee, and Ohio. Nothing derived from adipose tissue is FDA approved for any disease, and banking guarantees no eligibility, access, or benefit later. Ask your own licensed provider.
Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Minnesota readers weighing adipose tissue banking for potential future use can review current pricing or send their questions through the contact page.
Save My Fat partners with L2 Bio for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including neurology and neurosurgery input is required before publication. Please consult your neurologist or neurosurgeon before making any decisions about adipose tissue banking or research participation.
About the author: Oscar Tellez is the founder and CEO of Save My Fat. He holds a Bachelor of Science in Exercise Science and Health Promotion from Florida Atlantic University. He has spent more than a decade in the regenerative medicine industry across product distribution, laboratory and vendor relationships, and provider training. He is not a licensed clinician, and this article is educational, not medical advice.
Related guide: state stem cell laws.
